Additionally, INX-315 is currently in phase I/II trials for patients with recurrent or advanced/metastatic cancers, including HR+/HER2− breast cancer that has progressed following CDK4/6i therapy (NCT05735080). Here, CDK4 is linked to breast carcinoma.